INTRODUCTION
============

In an effort to generate experimental animals that might exhibit structural and functional changes in the brain as a result of life-long, moderately excessive release of glutamate from neurons, we created Tg (transgenic) mice that express the gene for *Glud1* (glutamate dehydrogenase 1) in CNS (central nervous system) neurons ([@B4]). Based on our observations with these Tg mice (*Glud1* mice), GLUD (glutamate dehydrogenase) appears to be a key enzyme in regulating the amount of glutamate synthesized and released from CNS neurons ([@B4]). This is an important observation, because the *Glud1* gene has been identified as a memory-related gene in the hippocampus ([@B11]) and dysregulation of a related *Glud* gene expressed in the human brain, *Glud2*, has been associated with early onset of Parkinson\'s disease ([@B38]). The reason for focusing on excess glutamate synthesis in CNS neurons is based on the fact that glutamate is not only the most prevalent excitatory neurotransmitter in the vertebrate CNS, but that it also has long-lasting effects on neuronal function, such as the establishment of long-term potentiation or depression of synaptic transmission ([@B1]; [@B14]; [@B27]), and on neuronal structure, such as the initiation of neuronal migration, axonal growth and synapse formation during development ([@B31]; [@B6]; [@B28]). Interest in the endogenous activity of glutamate goes beyond the role of this neurotransmitter in learning and memory. Acute treatment of neurons with high concentrations of glutamate leads to neurotoxicity, thus offering a possible link to neurodegenerative diseases ([@B13]).

In our previous study of heterozygous *Glud1* Tg mice, we found that chronic, moderate excess release of glutamate in these mice as compared with wt (wild-type) littermates, led to selective neuronal injury and moderate cell loss with advancing age ([@B4]). Overexpression of *Glud1* only in CNS neurons significantly increased synaptic glutamate release, decreased synaptic long-term potentiation and decreased synapse numbers in selective brain regions. The Tg mice used in these studies were mice that were back-crossed to the C57BL/6 strain, a strain of mice frequently used for biochemical, physiological and behavioural studies. However, it is known that isogenic lines of Tg mice produced through back-crossing with one strain may differ in their phenotypic characteristics from those produced using another inbred mouse strain ([@B16]). The diversity of phenotypic characteristics of Tg mice may result from behavioural, physiological or biochemical differences among such strains. For example, inbred strains of C57 mice, such as C57BL/6, have high levels of exploratory activity and low 'emotional' or anxiety levels, whereas albino inbred mice, such as the Balb/c strain, exhibit low levels of exploratory activity and high levels of anxiety ([@B15]; [@B30]). These two strains of mice differ also in several neurochemical parameters (i.e. endophenotype), including brain serotonin, the neurosteroid 17-OH-pregnenolone, and the formation of reactive oxygen species in hippocampal neurons in response to glutamate-induced stress ([@B46]; [@B43]; [@B37]). Other examples of endophenotypic variation among several strains of mice have been documented and include significant differences in the levels of gene and protein expression in the hippocampus ([@B19]; [@B39]).

It is possible to select different strains of mice to generate isogenic lines based on the expected effects that a transgene or targeted gene disruption would have on specific behaviours. However, in a situation such as the *Glud1* Tg mice for which the expected behavioural manifestations of the transgene are unknown, a choice of a specific strain on behavioural grounds is not possible. In such a situation, it is important to use more than one strain of mice as the background strain, especially strains that may significantly differ in terms of their behaviours and their physiological or biochemical characteristics. Therefore we decided to introduce the *Glud1* transgene into a second strain, one that we determined had endogenously lower levels of GLUD1 (glutamate dehydrogenase 1) enzyme activity in brain as compared with the C57BL/6 mice.

In the present study, we demonstrated that Balb/c mice had lower protein levels of GLUD1, as well as lower neuronal GLUD activity, therefore, fulfilling the criteria for a mouse strain with low endogenous GLUD1 expression that may be used for the generation of a new isogenic line of mice bearing the transgene for *Glud1*. Following back-crossing of the Tg mice to the Balb/c strain, we measured the effects that introduction of the *Glud1* gene had on basal extracellular glutamate levels and on depolarization-induced glutamate release from striatal neurons in these mice and compared such release with that observed in littermate wt mice and C57BL/6 mice overexpressing the same transgene. We decided to study striatal glutamate release based on previous results indicating dendrite and cell body injury (decreases in MAP2A labelling) but relatively well-preserved nerve endings (no changes in synaptophysin labelling) in the striatum of C57BL/6 *Glud1* mice ([@B4]). Unlike the striatum, the hippocampus of *Glud1* mice, and especially the CA1 region of the hippocampus, suffered dendrite and nerve terminal losses. Therefore glutamate release measurements in the striatum would not be compromised by substantial nerve terminal losses. In order to study glutamate release in these strains of mice, we utilized an enzyme-based MEA (microelectrode array) selective for measuring glutamate with low limits of detection (\<0.2 μM), high spatial resolution (333×15 μm), fast temporal resolution (500 ms) ([@B7]; [@B8], [@B9], [@B10]) and minimal damage to surrounding brain tissue (50--100 μm) ([@B23]).

METHODS
=======

Generation of Balb/c GLUD Tg mice
---------------------------------

All experimental procedures related to animals followed the procedures of the Institutional Animal Care and Use Committees of the University of Kansas and the University of Kentucky, as well as those of the National Institutes of Health. Efforts were made for minimizing the number of animals used. On arrival from the University of Kansas, mice (10--12 months of age) were quarantined for a minimum of 1 week in the DLAR (Division of Laboratory Animal Resources) at the University of Kentucky. Mice were group housed under a 12 h light/12 h dark regime with food and water *ad libitum*. All appropriate animal care (food, water, bedding, cage cleaning, etc.) was performed by DLAR staff. Following experimentation, the mice were killed with an overdose of anaesthetic followed by decapitation.

As previously described ([@B4]), Tg mice for *Glud1* were generated by microinjecting oocytes from hyper-ovulating C57BL6/SJL hybrid mice with linearized DNA containing the cDNA for mouse *Glud1* under the control of the promoter for neuron-specific enolase. The construct of the cDNA for *Glud1*, the oocyte microinjection procedure and the identification of the four founder mice carrying the transgene were described previously ([@B4]). The founder Tg mice were each cross-bred to Balb/c mice and heterozygous Tg mice identified by PCR methods ([@B4]). Cross-breeding with Balb/c mice has been carried out for more than ten generations.

Measurement of GLUD activity and GLUD1 protein levels in brain homogenates and synaptosomes
-------------------------------------------------------------------------------------------

Whole brains from adult C57BL/6, Balb/c and CD-1 mice were obtained following decapitation under anaesthesia (CO~2~) and were homogenized in ice-cold buffer (0.32 M sucrose, 0.5 mM MgSO~4~, 10 mM amino caproic acid, 0.1 mM EGTA, 0.1 mM benzamide, 0.1 mM benzamidine hydrochloride, in 10 mM Hepes buffer, pH 7.4). The homogenates were rapidly frozen in liquid N~2~ and stored at −80°C until used. Synaptosomes were isolated from freshly prepared brain homogenates using Ficoll™ gradient centrifugation procedures identical with those previously described ([@B12]). Protein content in all preparations was measured as described ([@B32]).

The enzyme activity of GLUD was measured in the direction of glutamate oxidation and deamination using a coupled reaction scheme similar to that described ([@B29]; [@B44]). In this scheme, the NADH formed during varying incubation time periods was allowed to reduce O~2~ to O~2~^−•^ and H~2~O~2~ in a coupled reaction with the electron mediator 1-MPMS (1-methoxy-5-methylphenazinium methyl-sulfate). The O~2~^−•^ and H~2~O~2~ formed were detected as light generated by the chemiluminescence reaction with isoluminol in the presence of m-POD (micro-peroxidase) ([@B29]; [@B44]). The GLUD enzyme reactions with brain homogenates were performed in 96-well chemiluminescence microplates and were initiated by the addition of 10 μl of homogenate (50 μg/ml final protein concentration) to 90 μl of reaction buffer (final concentrations in mM: 125.0 ammonium acetate, 1.0 EDTA, 0.9 NAD, 1.0 ADP, 1.0 leucine, 20.0 [l]{.smallcaps}-glutamate and 50.0 triethanolamine, pH 7.5). Following incubation at 23°C for 15 min, the NADH formed was estimated by adding to the wells 100 μl of 50 μM 1-MPMS and after 30 s, 100 μl of a 1:1 mixture of 0.24 mM isoluminol in 0.8 M carbonate buffer, pH 9.5, and 1 μM m-POD. The chemiluminescence signal was measured for 5 s at 15 s after the addition of isoluminol and m-POD. Different concentrations of NADH in the absence of any enzyme were used to measure the relationship of light emitted to NADH concentration and these values were used to estimate the specific activity of GLUD in brain homogenates. When purified liver GLUD1 enzyme activity was being measured for the standardization of the assay method, the protein added to the reaction buffer was 1 μg/ml final concentration.

The protein levels for GLUD1 in brain homogenates were estimated by two different procedures, immunoblot assays following SDS/PAGE of brain proteins and ELISA of *Glud1* in brain homogenates. These procedures were performed as previously described ([@B2]; [@B36]; [@B4]) using affinity-purified anti-GLUD1 antibody (1:1000 dilution, Sigma--Aldrich).

Glutamate measurements using MEAs
---------------------------------

Enzyme-based MEAs with Pt (platinum) recording surfaces were fabricated, assembled and calibrated for *in vivo* mouse recordings according to published literature ([@B25]; [@B8]). For selective glutamate recordings, two of the MEA recording sites were coated with an [l]{.smallcaps}-glutamate oxidase (EC 1.4.3.11) (Seikagaku America, East Falmouth, MA, U.S.A.) coating solution as previously described ([@B34]). The remaining two MEA recording sites (self-referencing or sentinel sites) were coated similar to the glutamate recording sites, with the exception that the coating solution did not contain [l]{.smallcaps}-glutamate oxidase. When the recorded sentinel site current was subtracted from the glutamate recording site current, the resulting signal represented the neuronal extracellular glutamate concentration ([@B7]; [@B9]).

All Pt recording surface were electroplated with mPD (1,3-phenylenediamine) (5 mM; Acros Organics; Morris Plains, NJ, U.S.A.) using the FAST16mkII recording system as previously described ([@B42]; [@B26]). This created an exclusion layer that restricts the passage of ascorbic acid, dopamine and 3,4-dihydroxyphenylacetic acid. Each MEA was calibrated prior to implantation as previously described ([@B34]). A total of nine MEAs were used in the present study and they had an average (±S.E.M.) glutamate sensitivity of 7.5±0.3 pA/μM, selectivity ratio of 127±27 to 1, and LOD (limit of detection) of 0.6±0.2 μM based on a signal-to-noise ratio of 3.

The MEA assemblies for *in vivo* recordings consisted of an enzyme-based working electrode and a single-barrel glass micropipette (internal tip diameter, 12--15 μm) positioned at an equal distance from the four recording electrode sites ([@B7]; [@B9]). Either an isotonic solution of 70 mM KCl (70 mM KCl, 79 mM NaCl and 2.5 mM CaCl~2~, pH 7.4) or a 5 mM glutamate solution (in physiological saline, pH 7.4) was loaded into the single-barrel glass micropipette. *Glud1* and wt mice were anaesthetized (1.25 g/kg urethane, intraperitoneally) and placed in a stereotaxic frame fitted with a mouse adaptor in a manner similar to that described recently ([@B9]; [@B4]). A 200-μm-diameter Ag/AgCl reference electrode was implanted into the frontal cortex at a site remote from the recording areas. The MEA assemblies were lowered into the striatum in steps of 500 μm ([@B21]) using the co-ordinates for mouse brain (from bregma: anteroposterior, +1.3; mediolateral, ±1.5; DV (dorsoventral), −2.25 mm to −3.75 mm; [@B20]). Solutions were ejected from the glass micropipette using a Picospritzer II (Parker Hannifin). The volume ejected was monitored using a stereomicroscope fitted with a reticule ([@B21]). Constant voltage amperometry was performed using a Fast Analytical Sensing Technology (FAST16mkII) electrochemistry instrument (Quanteon) and FAST software for four-channel simultaneous recordings ([@B7]).

A constant volume of 70 mM KCl (50--150 nl) was used to elicit glutamate release in the striatum of both groups. This stimulus range was chosen since volumes above 150 nl did not increase the amount of measurable glutamate. Therefore, the stimulus was determined to elicit the maximal amplitude of glutamate release (peak concentration in micromolar). After a stable baseline at each recording depth in the striatum was reached (∼10 min), ten signals per recording site were obtained. Stimulations were locally applied 1 min apart to allow sufficient clearance of the released glutamate from the extracellular space. These signals were averaged into a single data point, thus generating one data point for each DV position and a maximum of four data points per pass in the striatum of either hemisphere.

Amperometric data, time and pressure ejection marks for each individual Pt recording site were saved in the recording system. A modified Excel spreadsheet, in conjunction with individual electrode calibration constants, was used to analyse the glutamate curves. For the calculation of uptake rate kinetics (micromolar per second), only amplitudes of exogenously applied 5 mM [l]{.smallcaps}-glutamate (in physiological saline; pH 7.4) between 3 and 13 μM were used in the analyses. Uptake followed first-order-rate kinetics; therefore the uptake rate constant (*k*~−1~) was the logarithmic slope of glutamate concentration versus time (s^−1^) estimated by use of regression analyses (*R*^2^≥0.9). Multiplication of *k*~−1~ with the maximum amplitude of glutamate signal yielded the uptake rate (micromolar per second).

Statistical analyses
--------------------

Results from all assays were analysed using either one-way ANOVA with *post-hoc* pairwise analysis (Bonferroni) for multiple group comparisons, or by paired *t-*test for two group comparisons, as noted. For averaged glutamate release studies, a two-tailed *t*-test was used to compare Balb/c *Glud1* wt and Tg mice. In addition, a two-way ANOVA followed by a Bonferroni *post-hoc* was used to analyse recording depth variations in resting glutamate, depolarization-induced glutamate release and clearance of glutamate. Results are shown as means±S.E.M. and significance was defined as *P*\<0.05.

RESULTS
=======

Selection of a mouse strain with low endogenous GLUD1 activity
--------------------------------------------------------------

Based on previous behavioural observations that C57BL/6 exhibit very different behavioural characteristics than Balb/c mice, we decided to include these two strains in a direct comparison of relative enzyme activities and levels of the brain GLUD1 protein. As a control for the effects of mouse inbreeding, we also added an outbred strain, the CD-1 mice. In order to enhance the sensitivity of the GLUD assay procedure, we used a chemiluminescence detection method of coupled reactions as described in the Methods section ([@B29]; [@B44]). The limits of detection of NADH formed using the chemiluminescence procedure were approx. 1000-fold lower than those established using a fluorescence detection method (results not shown). Prior to the initiation of measurements of brain GLUD1 activity in the three mouse strains, the chemiluminescence procedure for the detection of glutamate oxidation and deamination by GLUD1 was validated using purified liver enzyme. The kinetic characterization of purified liver GLUD1 performed across different glutamate concentrations and in the presence of 0.9 mM NAD^+^ and the enzyme activators leucine and ADP (1 mM), led to an estimated *K*~m~ for the enzyme equal to 8.4 mM. This value of the *K*~m~ for glutamate of the purified liver GLUD1 measured at pH 7.5, was intermediate between the reported *K*~m~ for the enzyme measured at pH 6 (*K*~m~ = 22.7 mM) and that at pH 8 (*K*~m~ = 4.9 mM) ([@B3]). Thus, the chemiluminescence procedure appeared to be both sensitive and accurate in the detection of GLUD activity.

The enzyme activity in whole brain homogenates from C57BL/6, CD-1 and Balb/c, mice was measured at a single glutamate (20 mM) and NAD^+^ (0.9 mM) concentration, under conditions identical with those used for the liver enzyme, including the GLUD1 activators leucine and ADP. A high glutamate concentration was used so that the enzyme activity would approximate the *V*~max~ for GLUD1 as determined in the studies with purified liver enzyme. The NAD^+^ concentration used was near that of the estimated *K*~m~ for liver GLUD1 when measured in the presence of ADP ([@B3]). The results from the measurements of GLUD1 activity (glutamate deamination and oxidation) in brain homogenates from the three mouse strains indicated significantly lower enzyme activity in Balb/c as compared with either C57BL/6 or CD-1 mice ([Figure 1A](#F1){ref-type="fig"}). The outbred strain CD-1 had very similar GLUD1 activity to that of C57BL/6 ([Figure 1A](#F1){ref-type="fig"}).

![GLUD activity in C57BL/6, CD-1 and Balb/c mice\
GLUD activity in brain homogenates and isolated synaptosomes, and immune reactivity in brain homogenates from C57BL/6, CD-1 and Balb/c mice. (**A**) GLUD activity in brain homogenates from the three inbred strains. The results represent the means (±S.E.M.) of triplicate determinations obtained from five mice of each strain. Group comparison by one-way ANOVA indicated significant differences in GLUD activity of brain homogenates among the three strains (*F* = 13.41; *P* = 0.003). Pair-wise multiple comparisons of the three strains indicated significant differences (Bonferroni *t*-test) between the activity of homogenates from C57BL/6 and those from Balb/c, and between those from CD-1 and from Balb/c. The differences between C57BL/6 and CD-1 homogenates were not statistically significant. In all graphs, \*\**P*\<0.01 for pair-wise statistical comparisons of Balb/c versus C57BL/6 mice, and †*P*\<0.05 for comparisons of Balb/c versus CD-1 mice. (**B**) ELISA assays of immune reactivity of anti-GLUD1 antibodies with brain homogenates from the brains of the C57BL/6, CD-1 and Balb/c mice. Results represent the means±S.E.M. of relative immunoreactivity as compared with that of C57BL/6 (set as 100%). The results were from triplicate determinations with three mice in each inbred strain. Pair-wise statistical comparisons (*t*-test) indicated significant differences between the GLUD immune reactivity of C57BL/6 and Balb/c mice, and the immune reactivity of CD-1 and Balb/c mice. The differences in GLUD immune reactivity between C57BL/6 and CD-1 brain homogenates were not significant. Immunoblot demonstrations of differential levels of GLUD1 protein in the three inbred strains of mice are shown beneath this graph. Brain homogenates (30 μg protein per lane) from three mice from each strain were run on the same electrophoresis gel and labelled with anti-GLUD1 antibodies. Only one band of 60 kDa was labelled in all lanes containing brain samples. (**C**) GLUD activity in isolated synaptosomes from the brains of the three inbred strains. The results represent the means (±S.E.M.) of triplicate determinations obtained from three mice of each strain. Group comparison by one-way ANOVA indicated significant differences among the three strains (*F* = 22.24; *P* = 0.002). Pair-wise multiple comparisons of the three strains indicated significant differences (Bonferroni *t*-test) between C57BL/6 and Balb/c, and between CD-1 and Balb/c. The differences in GLUD activity between C57BL/6 and CD-1 synaptosomes were not significant.](an003e057f01){#F1}

The differences in GLUD1 activity might have been related to differential levels of the GLUD protein in the brains of Balb/c mice compared with those in C57BL/6 or CD-1. In order to explore this possibility, brain homogenates from C57BL/6, CD-1 and Balb/c mice were analysed by ELISA and immunoblot assays. Determination of the levels of immunoreactive protein by ELISA was indicative of significantly lower levels of GLUD1 protein in Balb/c brain homogenates than either those in C57BL/6 or CD-1 ([Figure 1B](#F1){ref-type="fig"}). Once again, there was no statistically significant difference detected between C57BL/6 and CD-1 GLUD1 levels in brain homogenates. The results from the ELISA assays were confirmed by the observations made in immunoblot assays ([Figure 1B](#F1){ref-type="fig"}). The antibody labelling of the band at 60 kDa corresponding to the GLUD1 protein in these blots was, again, significantly weaker in Balb/c mice compared with either C57BL/6 or CD-1 mice.

Using brain homogenates for the enzyme and immune assays of GLUD1 did not allow for the discrimination between neuronal and glial forms of GLUD1. In order to assess the activity of GLUD in a neuronal compartment, we isolated synaptosomes from brain homogenates of C57BL/6, CD-1 and Balb/c mice. Enzyme activity in synaptosomes was measured under conditions identical with those used for homogenates. Once again, GLUD activity in synaptosomes isolated from Balb/c mice was significantly lower than that of synaptosomes from C57BL/6 or CD-1 mouse brains ([Figure 1C](#F1){ref-type="fig"}). The GLUD activity in the purified synaptosome fraction from C57BL/6 brains (2.38 μmol/mg of protein, [Figure 1C](#F1){ref-type="fig"}) was substantially higher than that in whole brain homogenates from these mice (1.28 μmol/mg of protein, [Figure 1A](#F1){ref-type="fig"}), an indication that GLUD activity was enriched in this fraction that represented the intraneuronal compartment of synapses.

Resting glutamate levels in Balb/c Glud1 Tg mice
------------------------------------------------

In order to determine changes in tonic levels (i.e., basal levels) of striatal glutamate in Balb/c wt and Tg mice, resting glutamate levels were calculated in each mouse group as previously described ([@B17]; [@B41]; [@B24]). Briefly, the self-referencing electrode current was subtracted from the glutamate recording electrode current (and divided by the glutamate recording site slope obtained from *in vitro* calibration). As shown in [Figure 2(A)](#F2){ref-type="fig"}, there was no difference in resting glutamate levels in Balb/c *Glud1* wt (0.8±0.1 μM; *n* = 5) and Tg (0.8±0.2 μM; *n* = 4) mice. Because of the small size of our recording sites (333×15 μm), we were able to monitor resting glutamate levels in several DV positions in the striatum. As shown in [Figure 2(B)](#F2){ref-type="fig"}, this analysis indicated minor differences among the brain regions between Balb/c *Glud1* wt and Tg mice, and a two-way ANOVA showed no effect of the mouse genotype at any recording depth.

![Resting glutamate in the striatum of Balb/c *Glud1* mice\
Resting glutamate levels were determined in wt (*n* = 5) and Tg (*n* = 4) Balb/c mice at four DV positions (−2.25 to −3.75 mm in 0.5 mm increments) prior to 70 mM KCl depolarization-induced glutamate release studies. No differences in resting glutamate levels were observed across the entire striatum (A) or at different DV positions within the striatum (B).](an003e057f02){#F2}

Depolarization-induced glutamate release
----------------------------------------

Local application of 70 mM KCl for 1--2 s in the striatum of Tg and wt mice produced robust, reproducible changes in extracellular glutamate that were consistently higher in Tg mice ([Figure 3A](#F3){ref-type="fig"}). For consistency in data analysis, only glutamate signals elicited by ejections of 50--150 nl of 70 mM KCl were analysed to obtain the average maximum amplitude of glutamate release in the striatum of wt and Tg mice. Ejection volumes of KCl eliciting these signals were, on average, nearly identical in wt (111±4 nl) and Tg (116±3 nl) mice, yet the average maximum amplitude for glutamate release was significantly (*P*\<0.05) greater in Tg (5.2±0.4 μM) than wt (3.9±0.4 μM) Balb/c mice ([Figure 3B](#F3){ref-type="fig"}). Again, a depth analysis profile was performed and regional variations were observed between Balb/c wt and Tg mice ([Figure 3C](#F3){ref-type="fig"}). Analysis of the data by two-way ANOVA indicated a statistically significant effect of genotype (*F* = 6.39, *P* = 0.01) as well as a significant effect of interaction (*F* = 2.85, *P* = 0.04). Bonferroni *post-hoc* analysis revealed that at DV −3.25 striatal glutamate release was significantly (*P*\<0.01) greater in Balb/c Tg (6.1±0.7 μM) compared with wt (2.7±0.4 μM) mice.

![Depolarization-induced glutamate release\
(**A**) Stimulus-evoked glutamate release in Balb/c wt (black) and Tg (grey) mice following pressure ejection of 50--150 nl of 70 mM KCl (pH 7.4) in the striatum as indicated by the arrows. Reproducible signals of glutamate release were obtained from both mouse groups, Signals of glutamate release from striatal neurons of Balb/c *Glud1* Tg mice were consistently greater than those recorded from neurons of wt mice. (**B**) The average volumes of 70 mM KCl used to elicit depolarization-induced striatal glutamate release were: wt = 111±4 nl and Tg = 116±3 nl. These values did not differ significantly. The average maximal amplitude of KCl-induced glutamate release was significantly greater (\**P*\<0.05) in the striatum of Balb/c *Glud1* Tg (*n* = 4) mice compared with wt Balb/c mice (*n* = 5). (**C**) Depth-related alterations in average amplitude of stimulus-evoked glutamate release in the same two mouse groups as in (**B**). Analysis of data using two-way ANOVA with Bonferroni *post-hoc* indicated a significant (\*\**P*\<0.01) increase in stimulus-evoked glutamate release at DV −3.25 in the Balb/c *Glud1* Tg (*n* = 4) compared with glutamate release recordings at the same depth in wt littermates (*n* = 5).](an003e057f03){#F3}

Clearance of 5 mM l-glutamate
-----------------------------

In order to assess the role that glutamate transport might play in the differential levels of glutamate release in striatum following depolarization, glutamate transport into neurons or glia in the vicinity of the MEAs was also estimated by measuring glutamate clearance after local application of nanolitre volumes of 5 mM [l]{.smallcaps}-glutamate. Since neurotransmitter uptake follows Michaelis--Menten kinetics ([@B33]) and is known to be affected by the amount of available substrate, glutamate clearance was analysed by selecting a subset of signals with maximum release values in the range of 3--13 μM (amplitude matched). This concentration range was chosen because pressure ejection peak glutamate values in this range were quite reproducible in both Balb/c wt (7.8±0.3 μM, *n* = 5) and Tg (8.3±0.3 μM, *n* = 4) mice. The volume of 5 mM [l]{.smallcaps}-glutamate solution ejected from the glass micropipette was also similar in Balb/c *Glud1* wt (26±1 nl) and Tg (28±3 nl) mice. Within the subset of signals representing the concentration range selected, clearance rates of exogenously applied 5 mM [l]{.smallcaps}-glutamate were similar for wt (2.5±0.2 μM/s) and Tg (2.4±0.2 μM/s) mice ([Figure 4A](#F4){ref-type="fig"}). Also, a depth analysis profile revealed no regional variation in the clearance of exogenously applied glutamate in the striatum ([Figure 4B](#F4){ref-type="fig"}).

![Clearance rate of exogenously applied 5 mM glutamate\
(**A**) The clearance rate of exogenously applied 5 mM [l]{.smallcaps}-glutamate to the mouse striatum was analysed by selecting a subset of signals with maximum release values in the range of 3--13 μM. Peak values were similar in both Balb/c wt (7.8±0.3 μM, *n* = 5) and Tg (8.3±0.3 μM; *n* = 4) mice as was the rate of clearance. (**B**) When a depth profile was performed, no differences were observed in the clearance rate of exogenously applied 5 mM [l]{.smallcaps}-glutamate between wt and Tg *Glud1* Balb/c mice.](an003e057f04){#F4}

Depolarization-induced glutamate release in Balb/c compared with C57BL/6 mice
-----------------------------------------------------------------------------

Since the main focus of the present study was to determine whether the background strain of mice to which the founder *Glud1* Tg mice were back-crossed had any effects on synaptic glutamate formation and release *in vivo,* we directly compared depolarization-induced glutamate release in wt and Tg Balb/c and C57BL/6 mice. We previously showed that overexpression of the *Glud1* gene in mice back-crossed to C57BL/6 mice significantly increases depolarization-induced glutamate release in these Tg mice compared with wt littermates ([@B4]). Again, for consistency in data analysis, only glutamate signals elicited by ejections of 50--150 nl of 70 mM KCl in the striatum of Balb/c and C57BL/6 Tg and wt mice were analysed to obtain the average maximum amplitude of glutamate release in all groups (volume matched). Volumes of the KCl stimulus were similar in Balb/c wt (111±4 nl) to those in C57BL/6 wt (117±4 nl), and the same was true for Balb/c Tg (116±3 nl) and C57BL/6 Tg (120±6 nl) mice. The C57BL/6 mice released significantly more glutamate compared with the Balb/c mice ([Figure 5](#F5){ref-type="fig"}). A two-tailed *t*-test indicated that depolarization-induced glutamate release was significantly lower in the Balb/c mice, either wt or Tg (results presented above) when compared with the glutamate release values of the respective genotype of C57BL/6 mice: wt, 6.4±1.0 μM, *n* = 9; *P*\<0.01; and Tg: 10.2±1.7 μM; *n* = 5; *P*\<0.001. In other words, the Balb/c wt and *Glud1* Tg mice released 51--61% of the amount of glutamate released following stimulation of striatal neurons in C57BL/6 wt and *Glud1* Tg mice respectively.

![Depolarization-induced glutamate release in Balb/c versus C57BL/6 *Glud1* mice\
The average volume of 70 mM KCl used to elicit striatal glutamate release was similar in Balb/c wt (111±4 nl; *n* = 5) and Tg (116±3 nl; *n* = 4) mice, as well as in C57BL/6 wt (117±4 nl; *n* = 9) and Tg (120±6 nl; *n* = 5). Depolarization-induced glutamate release was decreased in Balb/c *Glud1* wt (3.9±0.4 μM) and Tg (5.2±0.4 μM) mice compared with C57BL/6 *Glud1* wt (6.4±1.0 μM) and Tg (10.2±1.7 μM) mice. \*\**P*\<0.01, \*\*\**P*\<0.001.](an003e057f05){#F5}

DISCUSSION
==========

The observations made in our current studies that the Balb/c mouse neurons had significantly lower endogenous levels of GLUD enzyme activity and GLUD1 protein in comparison with either C57BL/6 or an outbred strain, CD-1, are consistent with the results of a recent proteomic analysis of differential protein levels in the hippocampus of five inbred strains of mice ([@B40]). In that study, it was shown that Balb/c mice had the lowest GLUD1 protein levels of all strains examined ([@B40]). Thus the differences we detected between Balb/c and C57BL/6 in the levels of GLUD1 protein in whole brain homogenates or synaptosomes appear to be a molecular characteristic of this strain of mice. Our findings were indicative of a diminished function of total GLUD enzyme activity in whole brain and in synaptosomes of Balb/c versus C57BL/6 or CD-1 mice. The low GLUD activity and low GLUD1 protein levels thus led us to select the Balb/c mouse strain for the back-crossing of the *Glud1* Tg mouse founders. The procedures used for back-crossing and genotyping of mice were identical for both the C57BL/6 and the Balb/c mice ([@B4]). The endophenotypic effects of overexpression of the *Glud1* gene on brain function in the *Glud1* Tg Balb/c mice were assessed as the change in glutamate release following KCl depolarization of neurons.

Resting glutamate levels in Balb/c *Glud1* wt and Tg mice were nearly identical, suggesting that the overexpression of neuronal *Glud1* had no effect on the tonic levels of extracellular glutamate. Unfortunately, these values may be misleading owing to the potential effects of urethane anaesthesia on tonic levels of glutamate *in vivo*. Urethane exerts its effects predominantly through neurotransmitter-gated ion channels to enhance inhibitory synaptic neurotransmission as well as inhibit excitatory neurotransmission ([@B22]). Our laboratory has observed that resting glutamate levels in brain are attenuated by 60--80% in urethane-anaesthetized animals compared with freely moving rats ([@B41]). In fact, the tonic levels of glutamate reported in the present study were reduced by ∼80% compared with previously reported resting glutamate values in awake, freely moving mice (∼5 μM; [@B24]). These results are indicative of the need to exercise caution when interpreting tonic levels of glutamate (or other neurotransmitters) in anaesthetized animals.

Pressure ejection of 70 mM KCl elicited robust and reproducible glutamate release in the striatum of both Balb/c and C57BL/6 mice. This release was significantly increased in the Balb/c *Glud1* Tg versus wt mice, a finding that was similar to the previously observed increases in depolarization-induced glutamate release in *Glud1* Tg C57BL/6 mice ([@B4]). A depth analysis profile revealed that this increase in glutamate release occurred at a particular location within the striatum, at DV −3.25 mm. Importantly, at this same recording depth we did not observe any differences in the clearance of exogenously applied 5 mM [l]{.smallcaps}-glutamate between *Glud1* Balb/c wt and Tg mice. This indicates that the increase in depolarization-induced glutamate release was not the result of altered clearance characteristics in the Tg mice.

When we compared the depolarization-induced glutamate release in Balb/c mice with previously reported values for the C57BL/6 *Glud1* mice ([@B4]), an interesting trend emerged. Using similar volumes of stimulus, the average maximal amplitude of depolarization-induced glutamate release in Balb/c wt and *Glud1* Tg mice was 50--60% of the amount released in C57BL/6 mice. This lower level of evoked glutamate release corresponded to the decreased endogenous GLUD1 protein levels and GLUD activity that we observed in Balb/c compared with C57BL/6 mice.

One of the most intriguing findings from the current studies was the observation that depolarization-induced glutamate release was localized to the DV layer −3.25 within the striatum, even though GLUD1 overexpression occurred in all neurons in the brain ([@B4]). Unfortunately, limited data exist for the neuroanatomical connections of the mouse brain ([@B5]), particularly a region that lacks clear cytoarchitecture such as the striatum ([@B45]), thus making interpretation of the results obtained from this specific sub-region difficult. In mouse brain, it has previously been shown that glutamatergic afferents to the striatum originate in either the cortex (60%) or the thalamus (40%) and may form synaptic contacts on the same medium spiny neurons, yet it is the thalamostriatal neurons that have a higher release probability as compared with corticostriatal inputs ([@B18]). At DV −3.25, we may have recorded from a unique proportion of these thalamostriatal neuronal terminals and that these terminals might be the ones that were selectively altered in the Balb/c *Glud1* Tg mice, resulting in the increased glutamate release.

A particular strength of using MEAs, especially compared with other *in vivo* recording techniques such as microdialysis, is the capability afforded by these electrodes to investigate glutamate temporal dynamics at several recording depths of a layered structure, such as the striatum. The heterogeneity of multi-layered brain structures has been well characterized in a number of studies using electrochemical methods. Using carbon-fibre electrodes, [@B21] demonstrated a DV striatal gradient with respect to the amount of potassium stimulation needed to evoke dopamine release. [@B34] showed that the glutamate clearance time was increased in the dorsal versus ventral striatum as a function of aging in the Fischer 344 rat. More recently, [@B42] showed significant changes in stimulus-evoked release and re-uptake of glutamate in different hippocampal subregions with respect to aging in the Fischer 344 rat. Collectively, these results support the idea that nerve terminal projections within a specific brain structure are not homogeneous in terms of distribution and/or excitability, and it is necessary to analyse multiple depths and not simply infer that results obtained from a single layer are representative of the structure as a whole ([@B34]).

The primary finding of our study was that Balb/c *Glud1* Tg mice had significantly increased depolarization-induced glutamate release compared with wt littermates, which was similar to the results obtained with the C57BL/6 mice ([@B4]). These observations were a clear indication that introduction of the *Glud1* transgene in neurons of phenotypically and endophenotypically different strains of mice had very similar effects on neuronal release of glutamate. Furthermore, these results provide strong evidence for the importance of the *Glud1* gene in synaptic glutamate neurotransmission. The development of this *Glud1*-overexpressing mouse model may allow for the exploration of issues such as how chronic exposure of neurons to elevated glutamate levels can affect the control of various behavioural processes and of key molecular events that are hypothesized to occur during aging and in neurodegenerative disorders. While no behavioural changes were observed with the mice used in the present study, further experiments are being conducted to determine any behavioural phenotypes elicited by overexpression of *Glud1* with respect to age.
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